Posted by Michael Wonder on 01 Apr 2025
ICER publishes final evidence report on treatment for acute pain
31 March 2025 - Independent appraisal committee vote was split on the net health benefit of suzetrigine compared to non-systemic therapies; suzetrigine has potential to be cost saving due to avoided future cases of opioid use disorder.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of suzetrigine (Journavx, Vertex Pharmaceuticals) for the treatment of acute pain.
